SCHEMBL1644705

SCHEMBL1644705

CC(C)(C)[Si](C)(C)OCCNc1cccc(Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.38
GAA P10253 3/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
AGTR1 P30556 1/20 0.38
CYP3A4 P08684 3/20 0.34
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CYP1A2 P05177 4/20 0.33
CYP2C19 P33261 3/20 0.33
ALOX15 P16050 1/20 0.33
HIF1A Q16665 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GLA P06280 1/20 0.33
CYP2C9 P11712 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6027182 0.84 NPSR1 (0.41) ALDH1A1HPGDHSD17B10KDM4EMEN1
SCHEMBL29971364 0.80 CYP1A2 (0.48) ALDH1A1GAAMAPTHPGDAGTR1
SCHEMBL4647621 0.79 CYP1A2 (0.38) ALDH1A1CYP3A4CYP1A2CYP2C19ALOX15
SCHEMBL4035843 0.77 CYP2C19 (0.50) ALDH1A1GAAHPGDTSHRCYP1A2
SCHEMBL31024211 0.74 SMN1; SMN2 (0.40) ALDH1A1GAASMN1; SMN2HSD17B10KDM4E
SCHEMBL30821524 0.74 SMN1; SMN2 (0.49) ALDH1A1GAAMAPTHPGDAGTR1
SCHEMBL989193 0.74 SMN1; SMN2 (0.39) ALDH1A1MAPTSMN1; SMN2HSD17B10KDM4E
SCHEMBL31637989 0.74 CA12 (0.39) CYP3A4TSHRCA12CA1CA2
SCHEMBL20037490 0.72 DUT (0.32) SMN1; SMN2DUT
SCHEMBL5313454 0.72 CYP3A4 (0.40) ALDH1A1GAAMAPTHPGDAGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097413-B1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2013-12-25 EP disclosed
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 US disclosed
EP-2303329-A1 ANTIFUNGAL COMBINATION THERAPY F2G Limited (GB) 2011-04-06 EP disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 WO disclosed
EP-2097413-A1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G Limited (GB) 2009-09-09 EP disclosed
WO-2008062182-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 ALDH1A1 318/4885GAA 228/4885MAPT 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.